Related Experiment Video
Updated: Aug 20, 2026
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
[Soluble PD-1 can augment anti-tumor immunity induced by HSP70-peptide complex in tumor-bearing mice]
Xiao-hong Wang1, Gui-mei Zhang, Yu-fei He
1Department of Biochemistry & Molecular Biology, Tongji Medical College of Huazhong University of Sciences and Technology, Wuhan 430030, China. zhy1024@21cn.com
Aim:
To explore the effect of soluble PD-1 (sPD-1) on the anti-tumor immunity induced by HSP70-peptide.
Methods:
BALB/c mice were immunized with HSP70-peptide, then the cytotoxic activity of splenocytes was detected by MTT colorimetry. Expression of PD-1 and its ligand on splenocytes was determined by semi-quantitative RT-PCR. For some mice, sPD-1 plasmid was injected alone or in combination with HSP70-peptide and then the tumor weight and cytotoxic activity of splenocytes were measured.
Results:
sPD-1 alone had anti-tumor effect. HSP70-peptide complex not only induced tumor-specific cytotoxic T lymphocytes(CTLs), but also promoted expression of PD-1 and its ligand. The combination of sPD-1 with HSP70-peptide complex induced much more stronger anti-tumor effect as compared with sPD-1 or HSP70-peptide alone. sPD-1 transfection in mice could enhance the cytotoxic activity of splenocytes from immunized mice.
Conclusion:
sPD-1 enhanced the anti-tumor efficacy of HSP70-peptide.
